![]() ![]() Tewari noted a recent STAT News interview with FDA Commissioner Robert Califf said there could be potential for CMS coverage if clinical outcomes for patients without diabetes were "strikingly positive." Many investors had anticipated that CMS would need to see a reduction in major adverse cardiovascular events of about 17% or more to deem the results significant, Tewari said. ![]() Wells Fargo analyst Mohit Bansal said visibility on the bill is "low," but Select is the best support for arguing for a legal change. A bill known as the Treat and Reduce Obesity Act has already been proposed that could accomplish this. If CMS is able to reimburse patients for weight loss treatment that would significantly increase access, boosting sales. " to his estimated sales for Mounjaro and orforglipron. If this is the case, we don't need meaningful penetration into the obesity market to see meaningful upside. "At this point, it's hard to argue that the obesity class can simply be characterized as an aesthetic short-duration treatment market. "While it's likely that the price of GLP-1s will gradually decline, what SELECT fundamentally changes is the number of covered lives that can be reached & the duration of treatment," Tewari said. Notably, Medicare does reimburse obese patients for weight loss surgery, but Mounjaro has been able to help patients realize an average weight loss that approaches the typical success of bariatric procedures. Insurance coverage is critical because without payor support, out-of-pocket costs for these drugs can exceed $10,000 a year. Wells Fargo predicts Medicare is about half of the potential market for GLP-1 drugs. The Centers for Medicare and Medicaid Services, or CMS, manages the Medicare program and is currently forbidden from covering weight loss medications by law. "We think NVO opens the door to broader payer adoption & potential CMS coverage for the GLP-1 class," Tewari wrote in a research note Tuesday. Opening a door to broader access Jefferies analyst Akash Tewari raised his rating on Lilly shares to buy from neutral and said he was "meaningfully" increasing his Mounjaro peak sales estimate to $70 billion, and taking his orforglipron estimate to $8.5 billion. Lilly also has an experimental oral GLP-1 medicine, orforglipron, in development. It is currently on the market as a diabetes treatment. The drug, also known as tirzepatide, is expected to be approved for weight loss by the Food and Drug Administration by year-end. ![]() Analysts expect the Select study to benefit not only Novo but also Eli Lilly, which is working to get its Mounjaro approved to treat obesity. LLY YTD mountain Eli Lilly shares are up 45% year to date. Reducing this risk would be a big win for health insurers. Heart disease is the leading cause of death in the U.S., according to the Centers for Disease Control and Prevention. Although the full study hasn't been released yet or reviewed by outside scientists, the main takeaway was that Wegovy cut the risk of heart attack or stroke by 20%, which is much better than many analysts were expecting. Over a five-year period, those enrollees received either a 2.4-milligram dose of Wegovy or a placebo. That was a goal of the Select study, which tracked more than 17,000 adults age 45 and up with obesity or being overweight and a history of cardiovascular disease. For that reason, it has long been anticipated that broad-based insurance coverage would hinge on the drugmakers' ability to prove that losing weight is not about vanity but better health that translates into lower costs for insurers over the long run. GLP-1 agonists like Novo Nordisk's Ozempic and Wegovy have proven themselves to be effective in helping people shed pounds, but the treatments are pricey and weight can come back once patients stop the weekly injections. Personal Loans for 670 Credit Score or LowerĪ landmark study of the cardiovascular benefits of weight loss drug Wegovy is being seen as a pivotal step toward broadening access to these drugs. Personal Loans for 580 Credit Score or Lower Best Debt Consolidation Loans for Bad Credit ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |